PBAC's latest decision on Valsartan with hydrochlorothiazide: Recommended with restriction (2008). Considered for Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy.
PBAC outcome
Recommended with restriction
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
patients with hypertension who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
RCT, pharmacokinetic studies
Primary endpoint
mean change in blood pressure (mmHg)
Key trials
Study 301, Study 2301, Study 0201, Study 0201 (Pulse pressure responses), Mallion J-M et al., Lacourciere Y et al., Trenkwalder P et al., Fogari et al., Hua and Li, Della Chiesa et al., Schmidt et al., Waeber et al., Hilleman et al., Black et al.
Comparator
valsartan and hydrochlorothiazide given individually at equivalent doses
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated